Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Zoliflodacin: A Hope to Treat Antibiotic-Resistant Neisseria gonorrhea

Version 1 : Received: 30 March 2022 / Approved: 1 April 2022 / Online: 1 April 2022 (07:26:28 CEST)

How to cite: Mohammadi, M.R. Zoliflodacin: A Hope to Treat Antibiotic-Resistant Neisseria gonorrhea. Preprints 2022, 2022040004. Mohammadi, M.R. Zoliflodacin: A Hope to Treat Antibiotic-Resistant Neisseria gonorrhea. Preprints 2022, 2022040004.


Background: Neisseria gonorrhea is a gram negative diplococci leads to sexually transmitted infection. N.gonorrhoeae is an obligate human pathogen that causes infection to the mucus-secreting epithelial cells both in male and female. In 2017 the centre of disease control and World Health Organization published the list of global priority pathogens-12 with denting therapeutic options, including antibiotic-resistant N. gonorrhoeae. Aim: During the covid-19 pandemic, excessive use of antibiotics is occurring which has lead to its resistance. The infection is widespread and intractable. If this happens, more people will be left with an incurable infection which may cause serious health problems. The possibility of untreatable gonorrhea is emerging larger, and hence, it is the need of an hour to develop new drug for treating it Methods and material: We characterized thoroughly zoliflodacin antibiotic, its clinical trials and effect on human health by using different keywords like “zoliflodacin”, “covid-19”, “clinical trials” from different data sources like Pub-Med, Google-Scholar, and Science-Direct. Result: Zoliflodacin targets antibiotic-resistant gonorrhea. Zoliflodacin shows therapeutic approach against N. gonorrhea. It acts by inhibiting bacterial type 2 topoisomerase with binding site in bacterial gyrase. It shows promising results against N. gonorrhea. Zoliflodacin is effective in treating gonococcal urogenital and rectal infection. Discussion: Antibiotic is the only option to treat N. gonorrhea. There is no vaccine available to treat gonorrhea. The new drug, zoliflodacin, specifically targets antibiotic-resistant gonorrhea. This is giving a hope to researchers. In this study, we elaborate the discovery of zoliflodacin, its mechanism of action, the current clinical trials, and the effectiveness of zoliflodacin.


Neisseria gonorrhea; Zoliflodacin; Covid-19; Antibiotic-resistance; Treatment


Biology and Life Sciences, Immunology and Microbiology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0

Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.